Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9401)	10/15/2002 6:32:41 PM
From: tuck	Read Replies (1) \| Respond to of 9719

Of those, I like MLNM, now about $9.30 after hours. I think the market reverses tomorrow, and we'll get an opportunity to buy cheap again next week. I'll be looking to reload MLNM in the $8s. I also like KOSP if it takes part and goes back to the $10s. ACLA, I dunno, it looks like Fluidigm has the best next generation technology in the microfluidics space. I'd take CALP over ACLA at this point. ACLA rep told me in January they had all sorts of interest in ARTEAS, the challenge would be to pick the right partner. 10 months later, nada. You're aware ACLA's restricted cash is owed to CALP, right? Plus royalties. MEDX + ABGX, I suppose there wouldn't be antitrust concerns. With all the deals those two have signed, there ought to be plenty of news flow. Iressa news makes me wary of ABGX now. MEDX could be a good bottom fish, though. AFFX seems to report good numbers and pull back, then ramp up again. We might have to wait a while for that. Trickle was sooo close to buying that when it was $16 a few weeks ago, and has been kicking itself ever since for not doing so. 20-20 hindsight. At least, doubling down on QGENF was timed right. Cheers, Tuck